000304092 001__ 304092
000304092 005__ 20250831022510.0
000304092 0247_ $$2doi$$a10.1007/s00401-025-02926-y
000304092 0247_ $$2pmid$$apmid:40849395
000304092 0247_ $$2ISSN$$a0001-6322
000304092 0247_ $$2ISSN$$a1432-0533
000304092 0247_ $$2altmetric$$aaltmetric:180594446
000304092 037__ $$aDKFZ-2025-01760
000304092 041__ $$aEnglish
000304092 082__ $$a610
000304092 1001_ $$0P:(DE-He78)832f5277c0186f22e7704f1930239636$$aWeber, Katharina$$b0$$udkfz
000304092 245__ $$aDNA methylation analysis reveals an epigenetic signature distinctive of high-grade oligodendroglioma.
000304092 260__ $$aHeidelberg$$bSpringer$$c2025
000304092 3367_ $$2DRIVER$$aarticle
000304092 3367_ $$2DataCite$$aOutput Types/Journal article
000304092 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756189211_30613
000304092 3367_ $$2BibTeX$$aARTICLE
000304092 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304092 3367_ $$00$$2EndNote$$aJournal Article
000304092 500__ $$a#LA:B370#
000304092 520__ $$aIDH-mutant gliomas represent a subtype of diffuse gliomas that primarily affect patients in early to mid-adolescence. These tumors are classified into three distinct CNS WHO grades of malignancy. Accurate grading is essential for selecting an appropriate treatment maximizing anti-tumor efficacy while minimizing adverse effects. However, grading of oligodendrogliomas with 1p/19q codeletion currently relies on qualitative tumor characteristics that may be influenced by observer subjectivity, sampling bias, and tumor heterogeneity. This study aimed to explore DNA methylation-based tumor deconvolution into latent methylation components (LMCs) to evaluate their potential as objective grading tools in a cohort of 137 IDH-mutant gliomas. LMCs were analyzed in relation to malignancy markers, cellular composition, and underlying methylation signatures of the chromatin landscape. Glioma subtypes were associated with distinct LMCs. Two LMCs correlated with higher cellular density and advanced epigenetic age as well as with microvascular proliferation, necrosis, and epigenetically defined high-grade astrocytoma. The epigenetic patterns defining high-grade astrocytoma or oligodendroglioma, respectively, were similar. Higher-grade oligodendrogliomas, identified by LMC-based grading, were associated with more copy number alterations. Among patients of an external cohort who died during the assessment period, higher LMC1 proportions were associated with poorer overall survival. Therefore, LMCs hold the potential to support IDH-mutant glioma grading by incorporating objective epigenetic markers.
000304092 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000304092 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304092 650_7 $$2Other$$aCNS WHO grading
000304092 650_7 $$2Other$$aEpigenetic brain tumor classification
000304092 650_7 $$2Other$$aIDH mutant glioma
000304092 650_7 $$2Other$$aLatent methylation component
000304092 650_7 $$2Other$$aOligodendroglioma
000304092 650_7 $$0EC 1.1.1.41$$2NLM Chemicals$$aIsocitrate Dehydrogenase
000304092 650_2 $$2MeSH$$aHumans
000304092 650_2 $$2MeSH$$aDNA Methylation: genetics
000304092 650_2 $$2MeSH$$aOligodendroglioma: genetics
000304092 650_2 $$2MeSH$$aOligodendroglioma: pathology
000304092 650_2 $$2MeSH$$aBrain Neoplasms: genetics
000304092 650_2 $$2MeSH$$aBrain Neoplasms: pathology
000304092 650_2 $$2MeSH$$aMale
000304092 650_2 $$2MeSH$$aFemale
000304092 650_2 $$2MeSH$$aAdult
000304092 650_2 $$2MeSH$$aMiddle Aged
000304092 650_2 $$2MeSH$$aEpigenesis, Genetic: genetics
000304092 650_2 $$2MeSH$$aNeoplasm Grading
000304092 650_2 $$2MeSH$$aAged
000304092 650_2 $$2MeSH$$aYoung Adult
000304092 650_2 $$2MeSH$$aIsocitrate Dehydrogenase: genetics
000304092 650_2 $$2MeSH$$aMutation
000304092 650_2 $$2MeSH$$aAdolescent
000304092 7001_ $$aDettki, Mareike$$b1
000304092 7001_ $$aMünzberg, Marco$$b2
000304092 7001_ $$aZeiner, Pia Susann$$b3
000304092 7001_ $$aForster, Marie-Thérèse$$b4
000304092 7001_ $$aSteidl, Eike$$b5
000304092 7001_ $$aDivé, Iris$$b6
000304092 7001_ $$0P:(DE-He78)b15b56a6ed37417d476470c60c0140ff$$aHarter, Patrick$$b7
000304092 7001_ $$0P:(DE-He78)684b935434c8fe314d2cf6bd023d384b$$aScherer, Michael$$b8$$eLast author$$udkfz
000304092 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-025-02926-y$$gVol. 150, no. 1, p. 21$$n1$$p21$$tActa neuropathologica$$v150$$x0001-6322$$y2025
000304092 909CO $$ooai:inrepo02.dkfz.de:304092$$pVDB
000304092 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)832f5277c0186f22e7704f1930239636$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304092 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b15b56a6ed37417d476470c60c0140ff$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000304092 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)684b935434c8fe314d2cf6bd023d384b$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000304092 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000304092 9141_ $$y2025
000304092 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-11$$wger
000304092 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-11$$wger
000304092 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2022$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000304092 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bACTA NEUROPATHOL : 2022$$d2024-12-11
000304092 9202_ $$0I:(DE-He78)B370-20160331$$kB370$$lEpigenomik$$x0
000304092 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK Koordinierungsstelle Frankfurt$$x0
000304092 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x1
000304092 9201_ $$0I:(DE-He78)B370-20160331$$kB370$$lEpigenomik$$x2
000304092 980__ $$ajournal
000304092 980__ $$aVDB
000304092 980__ $$aI:(DE-He78)FM01-20160331
000304092 980__ $$aI:(DE-He78)MU01-20160331
000304092 980__ $$aI:(DE-He78)B370-20160331
000304092 980__ $$aUNRESTRICTED